San Francisco, California, 13th April 2022, ZEXPRWIRE, The European Society of Medicine (ESMED) recently published the research study “Intranasal Chlorpheniramine Maleate for the Treatment of COVID-19: Translational and Clinical Evidence” in Volume 10 Issue 3 of its Medical Research Archives. The multi-disciplinary study was conducted with the cooperation of universities and research facilities located in Utah, Florida, and Virginia in the United States of America, as well as Caracas, Venezuela. The authors of the study posited that the nasal cavity could be an ideal route of administration for interventions since it is the portal of entry of the severe acupressure respiratory syndrome coronavirus (SARS-CoV-2). The study aimed to demonstrate the feasibility and efficacy of intranasally administered Chlorpheniramine Maleate (CPM) spray to treat coronavirus disease 2019 (COVID-19).
The study used a two-phase, non-clinical to clinical approach. In the non-clinical phase, researchers evaluated CPM’s antiviral activity against SARS-CoV-2 delta (B.1.617.2) strain via a highly differentiated three-dimensional in vitro model of normal, human-derived tracheal/bronchial epithelial cells. CPM was tested in duplicate inserts of the tissue models of the human airway. Virus yield reduction assays measured antiviral activity on day six after infection. For the clinical phase, COVID-19 symptomatic (polymerase chain reaction positive) patients were recruited and assigned to a 7-day CPM treatment (n=32) or placebo (PLB; n=13).
Close safety monitoring of all patients was conducted before and after administering the drug. The primary outcomes monitored were time to symptom resolution (days), progression to hospitalization, emergency room visits, and symptoms of the severity of the disease using a visual analog scale (VAS) on a scale of 1-10 (no symptoms to worst symptoms). The results as summarized by the authors of the study demonstrated that the present two-phase study leads to a conclusion that CPM is an antiviral agent that can be administered intranasally to treat COVID-19 effectively. No subjects in the intervention group were hospitalized, whereas two in the group receiving placebo required hospitalization. Some subjects experienced mild discomfort after application of the CPM spray, but no participants reported side effects or adverse reactions.
For more information on the study and to read other scholarly work published by the European Society of Medicine, please visit https://esmed.org.
About the European Society of Medicine (ESMED)
The vision of the European Society of Medicine is a world connected for medical innovation. ESMED promotes this vision through its core values of Innovation, Excellence, Commitment, and Creativity. The European Society of Medicine publishes scholarly research on a wide variety of subjects in the field of medicine, including the ESMED Medical Research Archives, which offer a monthly issue compiling leading articles on current research. The European Society of Medicine exists to connect doctors with the knowledge they need to lead medical innovation and reduce the burden of disease. ESMED supports its members through facilitating cross-specialization networking, educational resources, and the free sharing of knowledge.
The Medical Research Archives (MRA) is an international scientific peer-reviewed journal committed to publishing research and clinical medicine in a timely and professional format. MRA is published both in print and online. As outlined by the European Society of Medicine, the MRA uses a double-blind peer review to ensure the quality, accuracy, and significance of accepted manuscripts. The editorial board is dedicated to maintaining the integrity and usefulness of the content published with MRA and strives to make content available in the newest and widest range of formats.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Times of Chennai journalist was involved in the writing and production of this article.